Gilead PrEP lenacapavir succeeds in Phase 3 trial
The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020. Mike Blake | Reuters Gilead‘s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received Gilead’s shot lenacapavir had contracted HIV by … Read more